[
  {
    "ts": "2026-02-28T00:18:59+00:00",
    "headline": "Eli Lilly’s Oral GLP‑1 Win And Olumiant Update Reshape Growth Story",
    "summary": "Eli Lilly (NYSE:LLY) reported Phase 3 data showing its oral GLP-1 candidate, orforglipron, produced greater blood sugar and weight reduction in adults with type 2 diabetes than Novo Nordisk’s oral semaglutide. The company has submitted regulatory filings for orforglipron in more than 40 countries, including for obesity, with potential US approval cited for Q2 2026. Lilly and Incyte received a positive opinion from the EMA’s CHMP for Olumiant to treat adolescents with severe alopecia areata...",
    "url": "https://finance.yahoo.com/news/eli-lilly-oral-glp-1-001859108.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b0b2251e-2b6d-3b82-bf22-f0e87de19a27",
      "content": {
        "id": "b0b2251e-2b6d-3b82-bf22-f0e87de19a27",
        "contentType": "STORY",
        "title": "Eli Lilly’s Oral GLP‑1 Win And Olumiant Update Reshape Growth Story",
        "description": "",
        "summary": "Eli Lilly (NYSE:LLY) reported Phase 3 data showing its oral GLP-1 candidate, orforglipron, produced greater blood sugar and weight reduction in adults with type 2 diabetes than Novo Nordisk’s oral semaglutide. The company has submitted regulatory filings for orforglipron in more than 40 countries, including for obesity, with potential US approval cited for Q2 2026. Lilly and Incyte received a positive opinion from the EMA’s CHMP for Olumiant to treat adolescents with severe alopecia areata...",
        "pubDate": "2026-02-28T00:18:59Z",
        "displayTime": "2026-02-28T00:18:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-oral-glp-1-001859108.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-oral-glp-1-001859108.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]